- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04878809
Rapid Screening Circuit of COVID 19 in Schools, Pilot Study
The outbreak of coronavirus disease 2019 (COVID-19), caused by acute respiratory syndrome severe coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread which poses a serious threat to public health. While 80% of the patients are asymptomatic or have a mild illness, 20% develop a serious illness. Predominant symptoms include fever, cough, and myalgias.
Most children have one mild or asymptomatic disease that can be resolved without medical attention and that, exceptionally, may progress to pneumonia and respiratory failure requiring hospitalization
Schools have started the course with strict protocols to prevent the transmission of SARS-Cov-2 among the members of the educational communities and thus avoid an uncontrollability of the epidemic. These protocols include scaled entrances in the centers and differentiated circulation to optimize compliance with social distance. They also include the creation of coexistence groups, the Ventilation of the spaces, hand washing, disinfection of furniture, and wearing a face mask. One key point in the prevention of infection is the rapid detection of infected individuals, their isolation immediate and quarantine, and screening of coexistence groups of positive cases. The diagnosis of Suspicious cases from both schools and other settings is done with a PCR, mostly in Primary Care Centers (PCC). This is causing an increased considerable volume of work for primary care centers.
In addition to the overload of the PCCs, the waiting time between sampling and PCR means that the person must remain at home until the result is obtained, with the negative impact that this means on the daily lives of students, teachers, and families. The use of a quick test performed on the own schools and with staff from the center itself trained to do this first screening would have three very relevant consequences for the system:
- Speed up the diagnosis and minimize the waiting time between the presentation of symptoms and quarantine of the whole group (if positive)
- Avoid a waiting time at home with the alteration - often unnecessary - of the day of students, their families, and school staff.
- Decongest the PCCs, receiving only the cases that need confirmation
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The outbreak of coronavirus disease 2019 (COVID-19), caused by acute respiratory syndrome severe coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread which poses a serious threat to public health. While 80% of the patients are asymptomatic or have a mild illness, 20% develop a serious illness. Predominant symptoms include fever, cough, and myalgias.
Most children have one mild or asymptomatic disease that can be resolved without medical attention and that, exceptionally, may progress to pneumonia and respiratory failure requiring hospitalization
Schools have started the course with strict protocols to prevent the transmission of SARS-Cov-2 among the members of the educational communities and thus avoid an uncontrollability of the epidemic. These protocols include scaled entrances in the centers and differentiated circulation to optimize compliance with social distance. They also include the creation of coexistence groups, the Ventilation of the spaces, hand washing, disinfection of furniture, and wearing a face mask. One key point in the prevention of infection is the rapid detection of infected individuals, their isolation immediate and quarantine, and screening of coexistence groups of positive cases. The diagnosis of Suspicious cases from both schools and other settings is done with a PCR, mostly in Primary Care Centers (PCC). This is causing an increased considerable volume of work for primary care centers.
In addition to the overload of the PCCs, the waiting time between sampling and PCR means that the person must remain at home until the result is obtained, with the negative impact that this means on the daily lives of students, teachers, and families. The use of a quick test performed on the own schools and with staff from the center itself trained to do this first screening would have three very relevant consequences for the system:
- Speed up the diagnosis and minimize the waiting time between the presentation of symptoms and quarantine of the whole group (if positive)
- Avoid a waiting time at home with the alteration - often unnecessary - of the day of students, their families, and school staff.
- Decongest the PCCs, receiving only the cases that need confirmation
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Barcelona, Spagna, 08017
- John Talabot
-
Barcelona, Spagna, 08022
- Escola l'Horitzó
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Students older than 6 years, teachers, administrative and service staff who attend regularly to L'Horitzó school.
- All participants will be required to sign an informed consent form performing a nasal and nasopharyngeal swab for performing a rapid detection test of antigens (In students under the age of 12, informed consent will be signed by their parent or legal tutor, in students equal to or older than 12 years, but under 18 consent it will be signed both by the student and by his / her parent or legal guardian. The participant over the age of 18 will sign the document in person, unless it is incapacitated, in which case you must sign your legal representative).
Exclusion Criteria:
• Not applicable
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Experimental group
People attending L'Horitzó School (students, teachers, administrative and service staff)
|
Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
|
Altro: Control Group
Escola John Talabot, will provide the incidence rate of infections by SARS-CoV-2
|
John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidence rate of people infected with SARS-CoV-2
Lasso di tempo: up to 8 weeks
|
Incidence rate of asymptomatic people infected with SARS-CoV-2, detected by rapid antigen detection tests in nasal swabs (self -taken)
|
up to 8 weeks
|
Incidence rate of people infected with SARS-CoV-2
Lasso di tempo: up to 8 weeks
|
Incidence rate of symptomatic/asymptomatic people infected with SARS-CoV-2, detected by rapid antigen detection tests in nasopharyngeal swabs performed by trained teachers from the school L'Horitzó
|
up to 8 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidence rate of people infected with SARS-CoV-2
Lasso di tempo: up to 8 weeks
|
Incidence rate of symptomatic people infected with SARS-CoV-2, detected by PCR nasopharyngeal performed under clinical practice.
|
up to 8 weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Boris Revollo Barriga, PhD, MD, Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ESCORAT
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su SARS-CoV-2 (COVID-19)
-
AstraZenecaAttivo, non reclutanteCOVID-19, SARS-CoV-2Giappone
-
Institute of Tropical Medicine, BelgiumJessa Hospital; University Hospital, Antwerp; Universiteit Antwerpen; Sciensano; Me...CompletatoCOVID-19 | SARS-CoV-2Belgio
-
SAb Biotherapeutics, Inc.Department of Health and Human Services; JPEO, Chemical, Biological, Radiological...CompletatoCOVID-19 | SARS-CoV-2Stati Uniti
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Completato
-
Syneos HealthUS Specialty Formulations, LLCCompletatoSARS-CoV-2 (COVID-19)Nuova Zelanda
-
Mayo ClinicCompletatoCOVID-19 | SARS-CoV-2Stati Uniti
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... e altri collaboratoriCompletatoMalattia respiratoria acuta SARS-CoV-2 | Sepsi SARS-CoV-2 | Infezione da SARS CoV 2Norvegia
-
University of MelbourneThe George Institute; The University of Queensland; The Peter Doherty Institute... e altri collaboratoriReclutamentoInfezione da SARS-CoV-2 (COVID-19)Australia
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute; Malaria Alert Center, Kamuzu University of Health SciencesReclutamentoInfezione da SARS CoV 2 | Vaccinazione SARS CoV 2Stati Uniti, Malawi
-
Medical University InnsbruckReclutamentoSARS-CoV-2 | Sindrome post-acuta da COVID-19Austria